Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Novavax COVID-19 Vaccine Efficacy in UK Adults
NCT04583995Phase 3Completed
- Sponsor
- Novavax
- Start
- Sep 2020
- Primary completion
- Mar 2022
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of NVX-CoV2373 in coronavirus disease 2019 (COVID-19), sponsored by Novavax. Started Sep 2020; status: completed.
02
Drugs
NVX-CoV2373
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04583995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04583995.